Lehmberg Kai, Nichols Kim E, Henter Jan-Inge, Girschikofsky Michael, Greenwood Tatiana, Jordan Michael, Kumar Ashish, Minkov Milen, La Rosée Paul, Weitzman Sheila
Department of Pediatric Hematology and Oncology, University Medical Center Eppendorf, Hamburg, Germany
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Haematologica. 2015 Aug;100(8):997-1004. doi: 10.3324/haematol.2015.123562.
The hyperinflammatory syndrome hemophagocytic lymphohistiocytosis can occur in the context of malignancies. Malignancy-triggered hemophagocytic lymphohistiocytosis should be regarded separately from hemophagocytic lymphohistiocytosis during chemotherapeutic treatment, which is frequently associated with an infectious trigger. The substantial overlap between the features of hemophagocytic lymphohistiocytosis with features of neoplasms makes its identification difficult when it occurs in malignant conditions. To facilitate recognition and diagnostic workup, and provide guidance regarding the treatment of malignancy-associated hemophagocytic lymphohistiocytosis, consensus recommendations were developed by the Study Group on Hemophagocytic Lymphohistiocytosis Subtypes of the Histiocyte Society, an interdisciplinary group consisting of pediatric and adult hemato-oncologists and immunologists.
高炎症综合征噬血细胞性淋巴组织细胞增生症可发生于恶性肿瘤背景下。恶性肿瘤引发的噬血细胞性淋巴组织细胞增生症应与化疗期间常由感染引发的噬血细胞性淋巴组织细胞增生症分开看待。噬血细胞性淋巴组织细胞增生症的特征与肿瘤特征之间存在大量重叠，这使得其在恶性疾病中发生时难以识别。为便于识别和诊断检查，并为恶性肿瘤相关噬血细胞性淋巴组织细胞增生症的治疗提供指导，组织细胞协会噬血细胞性淋巴组织细胞增生症亚型研究小组制定了共识性建议，该小组是一个由儿科和成人血液肿瘤学家及免疫学家组成的跨学科团队。
